TriangleNCT00939770 · CITED IN SOURCE DOCUMENTS
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2020-06-09
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib
Number of Participants With Toxicities of Crizotinib
Steady State C Max of Crizotinib
Steady State C Average of Crizotinib
Steady State AUC of Crizotinib
Steady State Clearance of Crizotinib
Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib
Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib
Number of Participants With Minimum Residual Disease (MRD)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients receiving the formulated capsules must have a body surface area (BSA) \>= 0.63 m\^2 at the time of study enrollment * Patients must have had histologic verification of malignancy at original diagnosis or relapse * \* Phase 1 (Part A1) - COMPLETE: Patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma (excluding patients with primary or metastatic central nervous system \[CNS\] tumors or patients with primary cutaneous ALCL) * \* Phase 1 (Part A2) - COMPLETE: Patients with confirmed ALK fusion proteins, ALK mutations, ALK amplification (defined as greater than 4-fold increase in the ALK signal number as compared to reference signal number on chromosome 2q arm) or MET proto-oncogene, receptor tyrosine kinase (MET) mutation or amplification; testing to confirm the presence of ALK fusion proteins, ALK mutations, ALK amplification or evidence of MET mutation or amplification for eligibility purposes must be performed as a Clinical Laboratory Improvement Act (CLIA)-certified assay; ALK immunohistochemistry can be used as a surrogate for fluorescent in situ hybridization (FISH) for patients with inflammatory myofibroblastic tumors (IMT) or ALCL * \*\* Note: Evidence for MET mutation or amplification is defined as: * Positive for c-Met amplification by FISH; or * Positive for known c-Met kinase domain activating mutations including V1110L, H1112L, H1112Y, H1124D, M1149T, T1191I, V1206L, L1213V, V1238I, M1268T, P1009S, T1010I, R988C, V941L, but excluding Y1248C, Y1248H, Y1248D, and Y1253D; or * Chromosomal translocations that lead to altered transcriptional regulation of c-Met and/or hepatocyte growth factor (HGF) including metastatic alveolar soft part sarcoma, clear cell sarcoma, rhabdomyosarcoma, or translocation associated renal cell carcinoma) * \* Phase 1 (Part A3) - COMPLETE: Patients with relapsed or refractory neuroblastoma, with or without bone marrow involvement, who are not eligible for Part A1 or A2 or cannot enroll on Part A1 because of stratum suspension or lack of available slots (these patients will be enrolled at one dose level below the dose level at which patients on Part A1 are actively enrolling) * \* Phase 2 (Part B): Patients with ALK+ relapsed or refractory neuroblastoma * \* Phase 2 (Part C): Patients with ALK+ relapsed or refractory ALCL (excluding patients with primary cutaneous ALCL) * \* Phase 2 (Part A2): Patients with diagnoses other than neuroblastoma or ALCL with confirmed ALK fusion proteins, ALK mutations, ALK amplification (defined as greater than 4-fold increase in the ALK signal number as compared to reference signal number on chromosome 2q arm) or MET mutation or amplification; testing to confirm the presence of ALK fusion proteins, ALK mutations, ALK amplification or evidence of MET mutation or amplification for eligibility purposes must be performed as a CLIA-certified assay; ALK immunohistochemistry can be used as a surrogate for FISH for patients with IMT * Disease status: * Phase 1 (Part A): Patients must have either measurable and/or evaluable disease * Phase 2 (Part B): Patients with neuroblastoma must have proven ALK+ disease with either measurable and/or evaluable disease as indicated below: * Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan or X-ray obtained within 2 weeks prior to study enrollment * Evaluable tumor by meta-iodobenzyl guanidine I 123 (MIBG) scan and/or bone marrow involvement with tumor cells seen on routine morphology * Phase 2 (Part C): Patients must have proven ALK+ disease with either measurable or evaluable disease * Performance level: Karnofsky \>= 50 for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age); Note: patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy: * Myelosuppressive chemotherapy: * Solid tumors: Patients with solid tumors must not have received chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea) * Lymphoma: Patients with lymphoma who relapse during standard maintenance therapy are eligible at time of relapse; for patients with ALCL who relapse while they are receiving cytotoxic therapy, at least 14 days must have elapsed since the completion of cytotoxic therapy; Note: cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of Crizotinib * At least 7 days since the completion of therapy with a growth factor * At least 7 days since the completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair * At least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody * \>= 2 weeks (wks) for local palliative radiation therapy (XRT) (small port); \>= 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; \>= 6 months must have elapsed if prior total body irradiation (TBI), craniospinal XRT or \>= 50% radiation of pelvis; \>= 6 wks must have elapsed if other substantial bone marrow (BM) radiation * Bone marrow/stem cell transplant or infusion without TBI: * Part A1 or Part C: No evidence of active graft vs host disease and \>= 3 months must have elapsed since stem cell transplant or infusion * Part A2, Part A3, or Part B: No evidence of active graft vs host disease and \>= 6 weeks must have elapsed since stem cell transplant or infusion * At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines * Patients must not have received prior therapy with Crizotinib * Patients on Part A1 or Part C of the study: * For patients with solid tumors or ALCL without bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \>= 1,000/mm\^3 * Platelet count \>= 75,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) * Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) * Patients with known bone marrow metastatic disease: * Peripheral absolute neutrophil count (ANC) \>= 750/mm\^3 * Platelet count \>= 25,000/mm\^3 (may receive platelet transfusions) * Hemoglobin \>= 8.0 g/dL (may receive RBC transfusions) * Not known to be refractory to RBC or platelet transfusions Transfusions are permitted to meet both the platelet and hemoglobin criteria; Note: patients with known bone marrow metastatic disease are not evaluable for hematological toxicity for the purposes of dose escalation * Patients eligible for Part A2, Part A3, or Part B of the study must meet the hematologic criteria below for enrollment: * Peripheral absolute neutrophil count (ANC) \>= 750/mm\^3 * Platelet count \>= 25,000/mm\^3 (may receive platelet transfusions) * Hemoglobin \>= 8.0 g/dL (may receive RBC transfusions) * Not known to be refractory to red cell or platelet transfusions Transfusions are permitted to meet both the platelet and hemoglobin criteria * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * 1 to \< 2 years: 0.6 mg/dL * 2 to \< 6 years: 0.8 mg/dL * 6 to \< 10 years: 1 mg/dL * 10 to \< 13 years: 1.2 mg/dL * 13 to \< 16 years: 1.5 mg/dL (male), 1.4 mg/dL (female) * \>= 16 years: 1.7 mg/dL (male), 1.4 mg/dL (female) * Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 110 U/L; for the purpose of this study, the ULN for SGPT is 45 U/L * Serum albumin \>= 2 g/dL * Corrected QT interval (QTc) =\< 480 msec * All patients and/or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines * Patients taking the capsule formulation must be able to swallow capsules; feeding tube administration is allowed for patients receiving the oral solution (OS) Exclusion Criteria: * Pregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method * Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents, with the exception of hydroxyurea for patients with ALCL, are not eligible * As Crizotinib is an inhibitor of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4), patients chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices including pimozide, aripiprazole, triazolam, ergotamine and halofantrine are not eligible; the topical use of these medications (if applicable) is allowed * Patients chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment, including but not limited to, ketoconazole, itraconazole, miconazole, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, delavirdine, nefazodone, diltiazem, verapamil, and grapefruit juice are not eligible; the topical use of these medications (if applicable), e.g. 2% ketoconazole cream, is allowed * Patients chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment, including but not limited to carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, tipranavir, ritonavir, and St. John's wort are not eligible; the topical use of these medications (if applicable) is allowed * Patients with known interstitial fibrosis or interstitial lung disease are not eligible * Patients with a known history of myocardial infarction or cerebrovascular accident are not eligible * Patients with central nervous system (CNS) tumors or known CNS metastases are not eligible; patients with a history of CNS metastases that have been surgically resected are eligible only if the baseline evaluation shows no evidence of current CNS metastases; patients with any evidence of CNS metastases on baseline evaluation are not eligible, regardless of whether the lesions have been previously treated and/or appear stable * Patients who have an uncontrolled infection are not eligible * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
- healthy Volunteers
- false
- maximum Age
- 21 Years
- minimum Age
- 1 Year
- sex
- ALL
- std Ages
- CHILD
- ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Other: Questionnaire Administration
- label
- Treatment (crizotinib)
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Treatment (crizotinib)
- description
- Given PO
- name
- Crizotinib
- other Names
- MET Tyrosine Kinase Inhibitor PF-02341066
- PF-02341066
- PF-2341066
- Xalkori
- type
- DRUG
- arm Group Labels
- Treatment (crizotinib)
- description
- Correlative studies
- name
- Laboratory Biomarker Analysis
- type
- OTHER
- arm Group Labels
- Treatment (crizotinib)
- description
- Correlative studies
- name
- Pharmacological Study
- type
- OTHER
- arm Group Labels
- Treatment (crizotinib)
- description
- Ancillary studies
- name
- Questionnaire Administration
- type
- OTHER
Study design
- intervention Model
- SEQUENTIAL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 122
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.
- measure
- Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib
- time Frame
- 28 days
- description
- The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.
- measure
- Number of Participants With Toxicities of Crizotinib
- time Frame
- Up to 30 days post-treatment
- description
- Mean with standard deviation of peak of serum concentration curve at steady state by dose level.
- measure
- Steady State C Max of Crizotinib
- time Frame
- Cycle 1 (day 15- 28) pre-dose, 1, 2,4, 6-8 hours post dose
- description
- Mean with standard deviation of average serum concentration curve at steady state by dose level.
- measure
- Steady State C Average of Crizotinib
- time Frame
- Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose
- description
- Mean with standard deviation of area under the serum concentration curve at steady state by dose level.
- measure
- Steady State AUC of Crizotinib
- time Frame
- Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose
- description
- Mean with standard deviation of the elimination of crizotinib at steady state by dose level.
- measure
- Steady State Clearance of Crizotinib
- time Frame
- Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hour post-dose
- secondary Outcomes
- description
- Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
- measure
- Number of Participants (Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (ALCL))With Response to Crizotinib
- time Frame
- Up to 8 years
- description
- Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
- measure
- Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib
- time Frame
- Up to 8 years
- description
- MRD status will be reported descriptively. The relationship between MRD status and clinical response to treatment will be examined in children with ALCL.
- measure
- Number of Participants With Minimum Residual Disease (MRD)
- time Frame
- Up to 8 years
Full study description
- brief Summary
- This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
- detailed Description
- PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and recommend a Phase 2 dose of Crizotinib administered orally twice daily to children with relapsed/refractory solid tumors and anaplastic large cell lymphoma (ALCL). (completed 2/15/13) II. To define and describe the toxicities of Crizotinib administered on this schedule. III. To characterize the pharmacokinetics of Crizotinib in children with refractory cancer. SECONDARY OBJECTIVES: I. To preliminarily define the anti-tumor activity of Crizotinib within the confines of a Phase 1 study. (completed 2/15/13) II. To obtain initial Phase 2 data on the anti-tumor activity of Crizotinib in children with relapsed/refractory neuroblastoma and ALCL. III. To preliminarily examine the relationship between anaplastic lymphoma kinase (ALK) status (e.g, the presence of a mutation, duplication, amplification, and/or translocation) in patients with neuroblastoma (NB) or ALCL and response to Crizotinib. IV. To preliminarily examine the relationship between minimal residual disease (MRD) status and clinical response to Crizotinib in patients with ALCL. V. To use a questionnaire to gather preliminary information on the palatability of the oral solution formulation of Crizotinib. VI. To evaluate for potential alterations in bone growth in pediatric patients. OUTLINE: This is a phase 1 dose-escalation study (completed 2/15/13) followed by a phase 2 study. Patients receive crizotinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Source references
- references
- citation
- Bartlett JA, Culver N, Santangelo M, Prpich A, Long E, Sagawa K, Shanker R, Xu H, Wilner K. Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation. Pharmaceut Med. 2026 May;40(3):193-207. doi: 10.1007/s40290-026-00604-2. Epub 2026 Apr 1.
- pmid
- 41920422
- type
- DERIVED
- citation
- Foster JH, Voss SD, Hall DC, Minard CG, Balis FM, Wilner K, Berg SL, Fox E, Adamson PC, Blaney SM, Weigel BJ, Mosse YP. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 1;27(13):3543-3548. doi: 10.1158/1078-0432.CCR-20-4224. Epub 2021 Feb 10.
- pmid
- 33568345
- type
- DERIVED
- citation
- Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017 Jan;79(1):181-187. doi: 10.1007/s00280-016-3220-6. Epub 2016 Dec 28.
- pmid
- 28032129
- type
- DERIVED
- citation
- Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.
- pmid
- 23598171
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-c40d3fde0c4d05ad036b
- requested nct id
- NCT00939770
- primary nct id
- NCT00939770
- source kind
- fda_spl_label
- source record id
- f5e01d3a-43fc-4fa6-b5dd-a07330b49328
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- payload sha256
- 6e544f92dfec00880ad36c44cd704e4e6b5612f99fb3aec7cc2117c8c7216ca0
- payload
- application numbers
- NDA217581
- NDA202570
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-c40d3fde0c4d05ad036b
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00939770
- occurrences
- context exact
- 7, NR) NR (14.5, NR) 14.2 Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma The efficacy of XALKORI was evaluated in Study ADVL0912 (NCT00939770), a multicenter, single arm, open-label study in patients 1 to ≤21 years of age that included 26 patients with relapsed or refractory, systemic ALK-positive AL
- end
- 9563
- exact text
- NCT00939770
- start
- 9552
- context exact
- LK-Positive Inflammatory Myofibroblastic Tumor Pediatric Patients with ALK-positive IMT Study ADVL0912 The efficacy of XALKORI was evaluated in Study ADVL0912 (NCT00939770), a multicenter, single-arm, open-label study in patients 1 to ≤21 years of age that included 14 pediatric patients with unresectable, recurrent, or refractory
- end
- 11776
- exact text
- NCT00939770
- start
- 11765
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00800.json
- source file sha256
- 8c4843bd18fc22d01ea4a91909737f3bbfdde09c17c5b243ce13d05c406cc6c7
- source json pointer
- /results/8/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- f5e01d3a-43fc-4fa6-b5dd-a07330b49328
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- cec3c8671bd01a99cb64545e3fbfc6d4a8ddbce28d4511b79db508f717ee737f
- spl effective time
- 20250722
- spl set id
- 2a51b0de-47d6-455e-a94c-d2c737b04ff7
Preserved source evidence · Not medical advice